SlideShare a Scribd company logo
1 of 20
Managing costs in higher-income countries David Cameron University of Edinburgh
Economics
Is there anything more to be said?
France Highest per capita health care expenditure in Europe including €14 billion each year on cancer. Estimated annual GDP loss of €17 billion from cancer. ~ 20% of all cancer spend is on drugs
Cost of treatment ,[object Object],[object Object],[object Object],[object Object]
Cost of treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Cost of treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
European cancer drug spend ,[object Object]
Rising drug costs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Productivity is falling… Even allowing for inflation, industry is investing twice as much in R&D as it was a decade ago to produce two-fifths of the new medicines…..
Solutions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
New models ? Phase I. Many drugs………………………… Phase II. Fewer drugs…………… Phase III.  Few drugs Phase I. € Phase II. €€ Phase III. €€€€€€€€€€€€€€€ Market €€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€ Phase I/II. Some drugs… Phase II/III smaller, less data Phase I/II. € Phase II/III. €€€€ Market €€€€€€€€€€€€€
Choice in spending
Choice in spending for society
So how to choose ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Lloyd A et al, British Journal of Cancer (2006) 95, 683 – 690
Price  ≠ Cost ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The future ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Make drug development  AND  drug use cost-effective

More Related Content

What's hot

HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVEHIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
iData Insights
 

What's hot (8)

Specialty one pager FINAL
Specialty one pager FINALSpecialty one pager FINAL
Specialty one pager FINAL
 
PillTime for Safer medicines
PillTime for Safer medicines PillTime for Safer medicines
PillTime for Safer medicines
 
Pharmacy Benefit Managers
Pharmacy Benefit ManagersPharmacy Benefit Managers
Pharmacy Benefit Managers
 
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVEHIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
 
How to monitor medicine prices
How to monitor medicine pricesHow to monitor medicine prices
How to monitor medicine prices
 
9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)
 
Pharmaceutical Industry Analysis 2013
Pharmaceutical Industry Analysis 2013Pharmaceutical Industry Analysis 2013
Pharmaceutical Industry Analysis 2013
 
Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?
 

Similar to ABC1 - D.A. Cameron - Managing costs in higher-income countries

Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27
gilberto lopes
 

Similar to ABC1 - D.A. Cameron - Managing costs in higher-income countries (20)

The value of generics and biosimilar drugs
The value of generics and biosimilar drugsThe value of generics and biosimilar drugs
The value of generics and biosimilar drugs
 
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
 
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
 
A look at potential remedies for a broken system
A look at potential remedies for a broken systemA look at potential remedies for a broken system
A look at potential remedies for a broken system
 
Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27
 
The Economics of Quality in Healthcare
The Economics of Quality in HealthcareThe Economics of Quality in Healthcare
The Economics of Quality in Healthcare
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019
 
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew HillGSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
 
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingWebinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug Pricing
 
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
 
0403 1 Stefan Weber - approaches to value and pricing
0403 1 Stefan Weber - approaches to value and pricing0403 1 Stefan Weber - approaches to value and pricing
0403 1 Stefan Weber - approaches to value and pricing
 
Clare Hague PhD, Pharma & Health Conference 2021
Clare Hague PhD, Pharma & Health Conference 2021Clare Hague PhD, Pharma & Health Conference 2021
Clare Hague PhD, Pharma & Health Conference 2021
 
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
 
St. David's Prophylaxis Program
St. David's Prophylaxis ProgramSt. David's Prophylaxis Program
St. David's Prophylaxis Program
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019
 
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
Pharmacoeconomics.ppt
Pharmacoeconomics.pptPharmacoeconomics.ppt
Pharmacoeconomics.ppt
 

More from European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
European School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
European School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
European School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
European School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
European School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
European School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
European School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
European School of Oncology
 

More from European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

Recently uploaded

Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Sheetaleventcompany
 
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
lizamodels9
 
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
daisycvs
 
Call Girls In Noida 959961⊹3876 Independent Escort Service Noida
Call Girls In Noida 959961⊹3876 Independent Escort Service NoidaCall Girls In Noida 959961⊹3876 Independent Escort Service Noida
Call Girls In Noida 959961⊹3876 Independent Escort Service Noida
dlhescort
 
Call Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service Bangalore
Call Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service BangaloreCall Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service Bangalore
Call Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service Bangalore
amitlee9823
 

Recently uploaded (20)

Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best ServicesMysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
 
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfDr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
 
Organizational Transformation Lead with Culture
Organizational Transformation Lead with CultureOrganizational Transformation Lead with Culture
Organizational Transformation Lead with Culture
 
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
 
Falcon's Invoice Discounting: Your Path to Prosperity
Falcon's Invoice Discounting: Your Path to ProsperityFalcon's Invoice Discounting: Your Path to Prosperity
Falcon's Invoice Discounting: Your Path to Prosperity
 
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Pune Just Call 9907093804 Top Class Call Girl Service Available
 
VVVIP Call Girls In Greater Kailash ➡️ Delhi ➡️ 9999965857 🚀 No Advance 24HRS...
VVVIP Call Girls In Greater Kailash ➡️ Delhi ➡️ 9999965857 🚀 No Advance 24HRS...VVVIP Call Girls In Greater Kailash ➡️ Delhi ➡️ 9999965857 🚀 No Advance 24HRS...
VVVIP Call Girls In Greater Kailash ➡️ Delhi ➡️ 9999965857 🚀 No Advance 24HRS...
 
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
 
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
 
RSA Conference Exhibitor List 2024 - Exhibitors Data
RSA Conference Exhibitor List 2024 - Exhibitors DataRSA Conference Exhibitor List 2024 - Exhibitors Data
RSA Conference Exhibitor List 2024 - Exhibitors Data
 
Call Girls Ludhiana Just Call 98765-12871 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 98765-12871 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 98765-12871 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 98765-12871 Top Class Call Girl Service Available
 
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
 
Business Model Canvas (BMC)- A new venture concept
Business Model Canvas (BMC)-  A new venture conceptBusiness Model Canvas (BMC)-  A new venture concept
Business Model Canvas (BMC)- A new venture concept
 
Pharma Works Profile of Karan Communications
Pharma Works Profile of Karan CommunicationsPharma Works Profile of Karan Communications
Pharma Works Profile of Karan Communications
 
Monthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptxMonthly Social Media Update April 2024 pptx.pptx
Monthly Social Media Update April 2024 pptx.pptx
 
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
 
Call Girls In Noida 959961⊹3876 Independent Escort Service Noida
Call Girls In Noida 959961⊹3876 Independent Escort Service NoidaCall Girls In Noida 959961⊹3876 Independent Escort Service Noida
Call Girls In Noida 959961⊹3876 Independent Escort Service Noida
 
Call Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service Bangalore
Call Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service BangaloreCall Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service Bangalore
Call Girls Hebbal Just Call 👗 7737669865 👗 Top Class Call Girl Service Bangalore
 
Falcon Invoice Discounting platform in india
Falcon Invoice Discounting platform in indiaFalcon Invoice Discounting platform in india
Falcon Invoice Discounting platform in india
 
Ensure the security of your HCL environment by applying the Zero Trust princi...
Ensure the security of your HCL environment by applying the Zero Trust princi...Ensure the security of your HCL environment by applying the Zero Trust princi...
Ensure the security of your HCL environment by applying the Zero Trust princi...
 

ABC1 - D.A. Cameron - Managing costs in higher-income countries

  • 1. Managing costs in higher-income countries David Cameron University of Edinburgh
  • 3. Is there anything more to be said?
  • 4. France Highest per capita health care expenditure in Europe including €14 billion each year on cancer. Estimated annual GDP loss of €17 billion from cancer. ~ 20% of all cancer spend is on drugs
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. Productivity is falling… Even allowing for inflation, industry is investing twice as much in R&D as it was a decade ago to produce two-fifths of the new medicines…..
  • 11.
  • 12. New models ? Phase I. Many drugs………………………… Phase II. Fewer drugs…………… Phase III. Few drugs Phase I. € Phase II. €€ Phase III. €€€€€€€€€€€€€€€ Market €€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€ Phase I/II. Some drugs… Phase II/III smaller, less data Phase I/II. € Phase II/III. €€€€ Market €€€€€€€€€€€€€
  • 14. Choice in spending for society
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20. Make drug development AND drug use cost-effective

Editor's Notes

  1. This slide has presented many times before, showing that whilst R&D spending has continued to increase, the number of new medicines approved has declined, so productivity of pharma R&D is falling.